Slide 1: Synopsis of the original article: CagriSema in type 2 diabetes phase 2 trial
Synopsis of the original article Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Frias JP, et al. Lancet. 2023; doi: 10.1016/S0140-6736(23)01163-7
Slide 2: Background
Background SCIENCEHUB.NOVONORDISK.COM Combining the GLP-1RA semaglutide with the long-acting amylin analogue cagrilintide has weight loss benefits The impact of combining these two drugs on HbA1c is unknown This phase 2 trial assessed the efficacy and safety of co-administered semaglutide with cagri
Slide 3: Methods
Methods SCIENCEHUB.NOVONORDISK.COM Adults with T2D OW s.c CagriSema 2.4 mg BMI ≥ 27 kg/m2 OW s.c semaglutide 2.4 mg and placebo Randomisation On metformin ± (1:1:1) OW s.c cagrilintide 2.4 mg and placebo SGLT2i 32 weeks Primary endpoint: Change from baseline in HbA1c Efficacy analyses: In all random
Slide 4: Results
Results Mean change in HbA1c Mean change in bodyweight Participants Adverse events from baseline to week 32 from baseline to week 32 0 0 Mean change, %-points SCIENCEHUB.NOVONORDISK.COM CagriSema n=31 Participants reporting adverse events -5.1 -0.5 Mean change, % -0.9 -5 -8.1 N=92 -1 Semaglutide n=3
Slide 5: Conclusions
Conclusions SCIENCEHUB.NOVONORDISK.COM In people with T2D, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters). The mean change in HbA1c with CagriSema was greater versus cagrilintide, but not versus semaglutide Treatment with CagriSe